<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109802/" ref="ordinalpos=2188&amp;ncbi_uid=6413001&amp;link_uid=PMC4109802" image-link="/pmc/articles/PMC4109802/figure/F2/" class="imagepopup">Figure 2. Scheme of neuroimmunomodulation of CD200 <span class="highlight" style="background-color:">signaling</span> by FGF2 <span class="highlight" style="background-color:">signaling</span>.  From: Fibroblast growth factor-2 <span class="highlight" style="background-color:">signaling</span> in neurogenesis and neurodegeneration. </a></div><br /><div class="p4l_captionBody">Activation of FGFR leads to enhanced CD200 expression, which leads to subsequent activation of anti-inflammatory pathways via microglial CD200 receptor (CD200R) activation. This pathway may be disturbed in AD patients due to CD200 decrease by amyloid-β (Aβ), pathogen-associated molecular patterns (PAMPs), or damage-associated molecular patterns (DAMPs) recognized by microglia, leading to neuroinflammation-induced suppression of LTP, synaptic transmission and neuronal viability in AD brain.</div></div>